Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
Tonix Pharmaceuticals will present preclinical data on its TNX-801 mpox vaccine candidate at the Vaccine Congress 2025, highlighting its potential to address public health threats.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is set to present new preclinical data on its TNX-801 mpox vaccine candidate at the Vaccine Congress 2025 in Vienna. The presentation, led by Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development, will focus on the vaccine's safety, immunogenicity, and efficacy in animal models. TNX-801, a recombinant horsepox virus live vaccine, has demonstrated protective efficacy against mpox and other orthopoxviruses after a single dose, suggesting its potential as a durable solution against emerging viral threats.
The company's initiative to develop TNX-801 is part of its broader commitment to addressing public health challenges, with plans to initiate clinical trials following the presentation. This development is significant as it represents a proactive approach to combating infectious diseases, leveraging innovative vaccine technology to potentially prevent future outbreaks. For more details on the announcement, visit https://ibn.fm/6hDuP.